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BACKGROUND: The precise timing of the angiogenic switch and the role of angiogenesis in the development of breast malignancy is
currently unknown.
METHODS: Therefore, the expression of CD31 (pan endothelial cells (ECs)), endoglin (actively proliferating ECs), hypoxia-inducible
factor-1 (HIF-1a), vascular endothelial growth factor-A (VEGF) and tissue factor (TF) were quantified in 140 surgical specimens
comprising normal human breast, benign and pre-malignant hyperplastic tissue, in situ and invasive breast cancer specimens.
RESULTS: Significant increases in angiogenesis (microvessel density) were observed between normal and benign hyperplastic breast
tissue (Po0.005), and between in situ and invasive carcinomas (Po0.0005). In addition, significant increases in proliferating ECs were
observed in benign hyperplastic breast compared with normal breast (Po0.05) cancers and in invasive compared with in situ cancers
(Po0.005). Hypoxia-inducible factor-1a, VEGF and TF expression were significantly associated with increases in both angiogenesis
and proliferating ECs (Po0.05). Moreover, HIF-1a was expressed by 60–75% of the hyperplastic lesions, and a significant association
was observed between VEGF and TF in ECs (Po0.005) and invasive tumour cells (Po0.01).
CONCLUSIONS: These findings are the first to suggest that the angiogenic switch, associated with increases in HIF-1a, VEGF and TF
expression, occurs at the onset of hyperplasia in the mammary duct, although the greatest increase in angiogenesis occurs with the
development of invasion.
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Breast cancer is the most frequently diagnosed cancer in women in
both Europe and the United States, with an estimated 608380 new
cases of invasive disease in 2007 (Ferlay et al, 2007). Breast cancer
is a genetically heterogeneous disease, and in contrast to the clearly
defined pathway from normal through adenomatous to invasive
malignancy associated with increasing dysplasia in colorectal
cancer, there is considerable uncertainty about the pathogenesis of
different forms of breast cancer and the relationship between
hyperplasia and carcinoma of the breast (Wiechmann & Kuerer,
2008). However, there is good evidence of an increased risk of
breast cancer associated with some hyperplastic lesions (for
example, atypical ductal hyperplasia; ADH) and clear evidence of
progression from in situ to invasive disease, particularly in high-
nuclear-grade lesions, although at a relatively low rate, for
example, 5–10% over 10 years (Jones, 2006).
Many cancer patients display a hypercoagulable state leading to
complications, such as deep vein thrombosis and pulmonary
embolism (reviewed by Bluff et al, 2008). Upregulation of tissue
factor (TF), the primary initiator of the coagulation cascade, has a
key role in this process (Molnar et al, 2007). In normal
physiological conditions, TF, a 47kDa transmembrane protein, is
constitutively expressed by subendothelial cells (such as pericytes,
smooth muscle cells and fibroblasts), whereas vascular endothelial
cells (ECs) and intravascular cells do not express TF (Abe et al,
1999). Initiation of the extrinsic coagulation pathway occurs when
TF is exposed to the bloodstream, either after damage to the
normal integrity of the vascular EC lining or on activation of
monocytes or ECs. Factor VIIa (FVIIa) then binds to TF on the cell
surface. Sequential downstream activation of haemostatic protease
complexes leads to the generation of thrombin, with subsequent
platelet activation and the formation of a fibrin clot, which restores
vessel integrity (reviewed by Rak et al, 2006).
During tumourigenesis, the strict regulation of TF expression is
lost. Upregulation of TF protein by tumour cells and associated
stromal cells has been well documented in breast cancer and other
malignant tumours, and may contribute to tumour angiogenesis,
metastasis, hypercoagulability and tumour cell survival (reviewed
by Bluff et al, 2008). Furthermore, correlations of elevated TF
expression with advanced stages of malignancy have been reported
in different cancers, including colon (Nakasaki et al, 2002) and
breast (Ueno et al, 2000), suggesting that TF may have a role in
tumour progression. In addition, TF is known to contribute to
tumour progression indirectly, through the role in haemostasis,
and, in part, by upregulating the pro-angiogenic vascular
endothelial growth factor-A (VEGF) (Zhang et al, 1994; Abe
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set al, 1999). VEGF, a 34–45kDa protein, is the most potent known
stimulator of angiogenesis (the outgrowth of new capillaries from
an existing vascular bed), an essential process in tumour growth,
progression and metastasis (Folkman, 1995). Although TF has the
potential to induce VEGF expression, the primary driving force for
angiogenesis is oxygen concentration, and VEGF is known to be
upregulated by hypoxia-inducible factor-1 (HIF-1a), in regions of
hypoxia within solid tumours (Mizukami et al, 2007).
The stage at which angiogenesis occurs in tumour progression
is known as the ‘angiogenic switch’ (Folkman et al, 1989).
Angiogenesis in invasive breast cancer is well documented (Bos
et al, 2005), but relatively few studies have addressed the role of
angiogenesis in pre-malignant ductal disease or where the
angiogenic switch occurs during the development of breast
malignancy. This study therefore quantifies angiogenesis and the
number of proliferating ECs in addition to the expression of HIF-
1a, VEGF and TF in hyperplastic lesions, in situ and invasive
breast carcinomas, to determine whether angiogenesis may have a
role in dysplastic transformation.
MATERIALS AND METHODS
Patients
Archival histological specimens were obtained from 140 patients at
the Royal Hallamshire Hospital between 1995 and 2003 with
approval from the Local Research Ethics Committee (Ethics
number SSREC 98/137). Haematoxylin and eosin sections of all
specimens were reviewed by SSC (a consultant histopathologist)
and these consisted of (a) normal breast tissue from patients
undergoing breast reduction surgery (n¼8); (b) benign hyper-
plastic breast tissue (usual ductal hyperplasia; UDH (n¼30));
(c) ADH (n¼27); (d) in situ cancer (ductal carcinoma in situ
(DCIS); low/intermediate nuclear grade (n¼19)); (e) high-
nuclear-grade DCIS (n¼25); and (f) invasive breast cancer
specimens (invasive ductal carcinoma; IDC; (n¼31)). Breast
cancer patients were excluded from the study if they received
neo-adjuvant treatment.
Immunohistochemistry
Formalin-fixed (10% formaldehyde), paraffin-embedded breast
specimens were sectioned (5mm) and mounted on 3-aminopropyl-
triethoxysilane (Sigma Aldrich, Dorset, UK)-coated slides. Im-
munohistochemistry was performed, at working concentrations of
10–25mgml
 1, using a panel of antibodies to human platelet EC
adhesion molecule-1 (PECAM-1/CD31; 20mgml
 1) (M0823; Dako-
cytomation Ltd, Cambridgeshire, UK), endoglin (CD105;
25mgml
 1) (M3527; Dakocytomation Ltd), HIF-1a (610959 BD
Pharmingen, Oxford, UK; 20mgml
 1), VEGF (A-20; Santa Cruz
Biotechnology, Wiltshire, UK; 10mgml
 1) and TF (4509; America
Diagnostica Inc, CT, USA; 20mgml
 1). A standard horseradish
peroxidase staining procedure was followed using an appro-
priate biotinylated secondary antibody (Vector laboratories,
Peterborough, UK) at 5–10mgml
 1, followed by the elite ABC kit
(Avidin:Biotinylated enzyme Complex; Vector laboratories) and
DAB (3, 30diaminobenzidine) as the chromogen substrate (Vector
laboratories). All sections were counterstained with Gill’s haema-
toxylin (Sigma Aldrich) to visualise cell nuclei. For HIF-1a
staining, antigen retrieval was performed by heating sections at
951C for 45min in target retrieval solution (Dakocytomation Ltd).
For all other antibodies, the same antigen retrieval was performed:
sections were heated in a microwave in TRIS/EDTA for 3min on
high power, followed by 7min on low power. Appropriate normal
sera and casein, both diluted 1:10 in phosphate-buffered saline,
were used for blocking all sections and dilution of antibodies.
Samples known to be positive for each factor (wounds and invasive
breast cancer tissue) were included in each staining run. Negative
controls were achieved by replacement of the primary antibody
with mouse IgG1-irrelevant antibodies. Furthermore, specificity of
the VEGF antibody was confirmed by pre-absorption with a
blocking peptide to VEGF (sc-152P; Santa Cruz Biotechnology). A
recombinant TF protein (2339-PA; R & D Systems, Oxfordshire,
UK) was used as a pre-absorption control for TF immunostaining
because no blocking peptides were available for this factor.
Microvascular density and proliferating EC assessment
Microvascular density (MVD), a surrogate marker of angiogenesis,
was assessed using the Chalkley grid method, as described previously
(Vermeulen et al, 2002). Briefly, the tissue was screened at low
magnification ( 40) for the five most microvascular dense areas
within each stained specimen (‘vascular hotspots’) that were
o150mm from any adjacent lesion. Subsequently, each vascular
hotspot was viewed at higher magnification ( 400) using a Chalkley
grid graticule, which has 25 randomly placed dots. Under high power,
the dots were aligned to touch the maximum number of vessels and
these were counted. This resulted in a Chalkley grid score for each
hotspot; the sum of the Chalkey scores for each of the five hotspots
was termed the cumulative Chalkley score (CCS). CD31 staining was
used to assess MVD; endoglin staining (CD105) was used to assess the
number of proliferating ECs in each breast specimen.
Quantification of HIF-1a, VEGF and TF staining
All analyses were carried out by an assessor fully trained by a
consultant histopathologist (SSC). HIF-1a staining was considered
to be positive when localised to the nuclei of 410% of ductal
epithelial cells (Chen et al, 2005). Pure cytoplasmic staining was
considered to be negative. Vascular endothelial growth factor-A
staining, if present in a lesion, was observed in 490% of cells; this
was assessed semi-quantitatively using a grading system, which
reflected the intensity of staining present within the specimen
(0¼no staining; 1¼weak staining; 2¼moderate staining; and
3¼strong staining). In contrast, HIF-1a and TF staining were
graded as present or absent, because no obvious differences in the
staining intensity of these factors were observed in the different
specimens examined. An invasive breast cancer specimen was
regarded as positive for TF expression when staining was identified
in 410% of the tumour cells in the section.
Intra- and interobserver error
The reproducibility of the Chalkley grids method for quantifying
MVD/proliferating ECs, HIF-1a, VEGF and TF staining was
established by at least 10% of the slides being counted by a
second experienced observer in a blinded manner. A selection of
the slides was also counted for a second time by the first observer.
Intra- and interobserver error was assessed 4 weeks apart, on 20
slides from each immunohistochemically stained group and
analysed statistically.
Follow-up
Follow-up information, including the date and cause of death, were
gathered by written enquires to the Trent Cancer Registry,
according to the ethics committee approval. Patients who had
died during the follow-up period from cancer-unrelated causes
were treated as censored by statistical survival analysis.
Statistical analysis
Statistical analysis was conducted using SPSS v15 software (SPSS
Inc. Chicago, IL, USA). Appropriate non-parametric tests were
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sused to investigate protein expression (Mann–Whitney U-test for
two independent groupings, Kruskal–Wallis test for more than
two independent groupings and Jonckheere–Terpstra test for
ordinal categorical groupings). If continuous data were not
normally distributed, correlations were analysed with Spearman’s
correlation statistics. Survival curves were plotted using the Cox
regression model and analysis was carried out using ‘death due to
breast cancer’ as the end point for overall survival. The influence of
MVD and number of proliferating ECs was assessed using the Cox
proportional hazards regression model. Data were considered
statistically significant at the level of Po0.05.
RESULTS
Assessment of angiogenesis
Strong CD31 staining was observed along the cell membrane of
ECs in all the breast specimens observed (Figure 1A). The median
CD31 MVD count was 14.5 in normal breast (range, 6–21;
Figure 1C), which increased significantly to 28 in benign
hyperplastic tissue (UDH) (range, 13–57; Po0.005). Microvascu-
lar density scores were constant in UDH/ADH breast samples and
in in situ cancers of all grades, but there was a further significant
increase in MVD between in situ and invasive carcinomas, with a
median MVD count of 31 (range, 14–56) in high-grade DCIS and
59 (range, 23–74) in IDC (Po0.0005).
The immunostaining of vessels with CD31 (pan ECs) exhibited
an increased frequency and intensity, when compared with
endoglin, in all types of breast tissues (Figure 1A and B). In
contrast to CD31 staining, endoglin was not expressed in normal
breast ECs, but was expressed by ECs in 17% of UDH cases, 19% of
ADH cases, 21% and 44% of DCIS cases (low/intermediate grade
and high grade, respectively) and in 84% of invasive carcinomas
(Figure 1D). Moreover, there was a significant correlation between
vessels staining for both endoglin and CD31 (Spearman’s rho
correlation coefficient¼0.516; Po0.005). The correlation coeffi-
cients for inter- and intraobserver error scores for MVD and
proliferating ECs were 0.91 and 0.86, and 0.92 and 0.89,
respectively, showing a high level of agreement.
Assessment of HIF-1a
Hypoxia-inducible factor-1a protein was not expressed in normal
breast tissue, but was expressed in the nuclei of ductal epithelial
cells in 65–75% of hyperplastic breast/in situ cancers (Figures 2A
and 3A) and in over 90% of invasive cancers (Figures 2B and 3A).
There was a moderate correlation between HIF-1a expression
and MVD (Spearman’s rho correlation coefficient¼0.502,
P¼0.001) and proliferating ECs (Spearman’s rho correlation
coefficient¼0.301, P¼0.001). The correlation coefficients for
inter- and intraobserver error scores for HIF-1a assessment were
0.88 and 0.91, respectively, showing a high level of agreement.
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Figure 1 Endothelial staining in breast lesions. Immunohistochemical staining of ECs with (A) CD31 and (B) endoglin in high-grade DCIS. Note the
increased frequency and intensity of stained ECs for CD31 compared with endoglin (scale¼50mm). Scatter plots representing cumulative Chalkley scores in
different breast tissue samples immunostained with (C) CD31 (MVD) and (D) endoglin (proliferating ECs). (C) There was a significant increase in MVD
between normal breast tissue and UDH (Po0.005), and a further significant increase in MVD between in situ (DCIS) and invasive breast cancers
(Po0.0005). (D) There was a significant increase in proliferating ECs in UDH cases compared with normal breast (Po0.05) and in IDC compared with high-
grade DCIS specimens (Po0.005). Po0.05 was considered significant (Kruskal–Wallis followed by Mann–Whitney U-test).
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Vascular endothelial growth factor-A was expressed in the
cytoplasm of ductal epithelial cells in 100% of breast specimens,
with weak and/or moderate expression in normal breast tissues
(Figures 2C and 3B), with moderate to strong expression in
hyperplastic tissue/in situ cancers (Figures 2D and 3B) and with
strong expression localised to invasive tumour cells (Figures 2E
and 3B). Vascular endothelial growth factor-A was also constitu-
tively expressed in breast ECs of normal, hyperplastic and DCIS
specimens (Figure 2F), but in contrast to VEGF staining in
epithelial cells, there was no change in the EC VEGF intensity in
different breast tissue types. Interestingly, most ECs within
invasive carcinomas did not express VEGF, whereas stromal cells,
such as macrophages and fibroblasts, (based on nuclear and
cellular morphology analysis) expressed VEGF in all the different
classes of breast tissue examined.
There was a strong correlation between VEGF expression
and MVD (Spearman’s rho correlation coefficient¼0.731,
P¼0.001) and proliferating ECs (Spearman’s rho correlation
coefficient¼0.576, P¼0.001), and a moderate correlation between
VEGF expression and HIF-1a (Spearman’s rho correlation
coefficient¼0.317, P¼0.001) in epithelial/tumour cells. The
correlation coefficients for inter- and intraobserver error scores
for VEGF assessment were 0.85 and 0.90, respectively, showing a
high level of agreement.
Assessment of TF
In contrast to the constitutive expression of VEGF in ductal
epithelial cells, TF was not expressed in normal/hyperplastic breast
epithelial cells or in in situ cancer cells, but interestingly, TF was
expressed by tumour cells in approximately 55% of invasive
carcinomas (Figure 2G). Tissue factor was not expressed by ECs in
normal breast tissue, but was expressed by some ECs in
hyperplastic tissue and in ECs associated with in situ cancer
(Figure 2H). Similar to the pattern of VEGF staining within the
intratumoural vasculature, ECs within invasive cancers rarely
expressed TF. Putative macrophages (based on nuclear morphol-
ogy analysis) expressed TF in all breast tissue types, except normal
breast (Figure 2I), and TF expression was also observed in
thrombosed vessels within IDC specimens (Figure 2J). The latter
were used as an internal positive control for TF immunostaining.
Moderate correlation was seen between TF expression and MVD
(Spearman’s rho correlation coefficient¼0.431, P¼0.001) and
proliferating ECs (Spearman’s rho correlation coefficient¼0.403,
P¼0.001), and a strong correlation between TF and VEGF
expression (Spearman’s rho correlation coefficient¼0.593,
P¼0.001) in epithelial/tumour cells. In contrast, there was no
correlation between TF and HIF-1a expression in epithelial/
tumour cells. The correlation coefficients for inter- and intraob-
server error scores for TF assessment were 0.89 and 0.93,
respectively, showing a high level of agreement.
Survival analysis
All patients with invasive breast cancer at the time of diagnosis
were followed up for a median of 71 months (range, 24–117
months). The Cox regression curve for MVD and proliferating ECs
(Figure 4) showed a decreased survival in invasive breast cancer
patients exhibiting a high CCS (greater than the median (59 for
MVD and 22 for proliferating ECs)) when compared with patients
Figure 2 Immunohistochemical staining for HIF-1a, VEGF and TF. (A) Nuclear HIF-1a staining in the ductal epithelial cells of an ADH case and (B)
tumour cells of an invasive cancer. (C) Weak expression of VEGF in normal breast epithelium (score¼1), (D) strong expression in florid usual ductal
hyperplasia (score¼2/3) and (E) strong staining localised to tumour cells within invasive breast carcinomas (score¼3). (F) VEGF expression in ECs in
normal breast tissue. (G) Tumour cells expressed TF in approximately 55% of invasive breast cancer specimens. (H) TF was expressed in ECs associated
with benign hyperplastic tissue (arrow). (I) Putative macrophages expressing TF associated with areas of DCIS (arrows). (J) TF expressed in vessel containing
thrombosis (arrow). Photographs A–E and G were taken at  20 magnification and all others at  40 magnification.
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swith a low CCS (equal to or less than median for both parameters),
which did not achieve significance (P¼0.09 and P¼0.12,
respectively), probably because of the relatively small numbers
of patients in the study.
DISCUSSION
The process of developing a high-density vascular network that
connects the tumour and host circulation, termed the ‘angiogenic
switch,’ is a crucial step for the progression of a tumour from a
benign to malignant state (Folkman et al, 1989). Although it
has been suggested that the initiation of angiogenesis occurs
simultaneous to invasion (reviewed by Bergers & Benjamin, 2003),
only one previous study has investigated angiogenesis at the
individual stages of the hyperplasia, in situ and invasive breast
carcinoma spectrum (Pavlakis et al, 2008). We show that
angiogenesis is significantly increased early in this sequence,
confirming this recent data, although the greatest increase occurs
with tumour invasion, with associated increases in HIF-1a, VEGF
and TF expression. Our data therefore suggest that angiogenesis is
initiated at the start of hyperplasia, with further increases between
in situ and invasive carcinomas. Angiogenesis thus starts with
hyperplasia before there is any morphological evidence of atypia.
Endoglin has been reported to be highly expressed in the
vasculature of various tumour types, including invasive breast
carcinomas (Wang et al, 1994; Beresford et al, 2006), and predicts
poor survival and poor clinical response to chemotherapy
(Charpin-Taranger et al, 2003; Dales et al, 2004; Beresford et al,
2006). To our knowledge, endoglin has not previously been
assessed in each stage of the hyperplasia, in situ and invasive
breast carcinoma sequence. The significant increase in the
percentage of specimens expressing endoglin in both high-grade
in situ and invasive carcinomas indicates increases in actively
proliferating vessels participating in angiogenesis. In agreement
with other studies (El-Gohary et al, 2007), we identified a
significant correlation between vessels stained with endoglin and
CD31. However, in this study, between one and two-thirds of the
vessels within pre-malignant, preinvasive and invasive breast
cancers exhibited proliferating ECs (based on CCS calculated with
CD31 and endoglin staining) in contrast to a report by Wang et al
(1994), which showed that endoglin stained only 20% of the vessels
highlighted by CD31 in invasive breast carcinomas.
Previous studies have showed that a high MVD significantly
predicts poor survival of breast cancer patients (both relapse-free
survival and overall survival) (Uzzan et al, 2004) as does a high
expression of endoglin (Charpin-Taranger et al, 2003; Dales et al,
2004). However, in this study, although patients with a high MVD
(459) and high number of proliferating ECs (422) tended to have
a poorer prognosis than patients with a low MVD (p59) and low
number of proliferating ECs (p22) to the same order of magnitude
as reported by the previous studies, these did not achieve
significance. This may be because of the relatively small number
of invasive cancer patients in this study, which was not primarily
designed to address this issue.
In addition, a positive correlation was observed between HIF-1a
and MVD, and between HIF-1a and proliferating ECs (based on
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Figure 4 Cox regression survival graphs. Comparison of overall survival
between groups of patients with pmedian and 4median cumulative
Chalkley scores (CCS) for (A) MVD (CD31; P¼0.09) and (B) proliferating
ECs (endoglin; P¼0.12).
Angiogenic switch in breast cancer
JE Bluff et al
670
British Journal of Cancer (2009) 101(4), 666–672 & 2009 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sendoglin expression). Endoglin expression associated with hypoxia
within solid tumours has been reported to be directly due to
HIF-1a binding to the hypoxia response element in the endoglin
promoter (Bos et al, 2005). As expected, we showed a significant
association between HIF-1a and VEGF in both ECs and epithelial/
tumour cells, as it is known that the HIF-1 complex recognises a
consensus hypoxia response element in the promoter of VEGF that
mediates hypoxic signals including angiogenesis. Much less
expected was the high percentage of hyperplastic breast lesions
that expressed HIF-1a, as a recent investigation reported that HIF-
1a was not expressed in hyperplastic lesions (Hao et al, 2007).
Although hypoxia is one of the most potent stimulators of VEGF,
interestingly, not all of the in situ and invasive cancers expressed
HIF-1a. Accumulating evidence indicates that HIF-1-independent
pathways can also control angiogenesis (Mizukami et al, 2004).
Knockdown of HIF-1a through small interfering RNA in a colon
cancer cell xenograft reduced tumour growth, but surprisingly did
not inhibit tumour angiogenesis (Mizukami et al, 2005). The
specific molecular mechanisms that underlie HIF-1-independent
regulation of VEGF are only now being elucidated, but the RAS
oncogene seems to have a pivotal role (Ryan et al, 2000; Mizukami
et al, 2004).
Although VEGF is a key mediator of angiogenesis in breast
cancer and it is well recognised that VEGF is upregulated in
invasive breast carcinomas (Borgstrom et al, 1999), much less is
known about VEGF expression in hyperplastic and preinvasive
lesions. Indeed, although VEGF expression has recently been
reported in hyperplastic epithelium (Pavlakis et al, 2008), this
study is the first to show that this is an upregulation compared
with normal breast tissue. The constitutive expression of VEGF in
normal breast endothelium may be related to the role of VEGF in
preventing apoptosis, which promotes EC survival (Gerber et al,
1998), although it is not yet clear how the breast vasculature
remains quiescent in the presence of VEGF. Vascular endothelial
growth factor-A expression has previously been shown to be
significantly associated with MVD in breast cancer (Bolat et al,
2006; Pavlakis et al, 2008). Moreover, the positive correlations seen
in this study between VEGF expression and both MVD and
proliferating ECs in hyperplasia, in situ and invasive breast
carcinoma spectrum indicates that VEGF has a key role in breast
cancer angiogenesis, most likely by binding to VEGF receptors on
ECs and inducing EC proliferation (Ferrara et al, 2003).
The upregulation of TF in invasive breast cancers may be related
to the role of TF in metastasis (Bromberg et al, 2001; Amarzguioui
et al, 2006; Ngo et al, 2007). Tissue factor is highly expressed in
metastatic, but not in non-metastatic breast carcinoma cells (Bluff
et al, 2006), and may contribute to the metastatic process directly
through the TF-FVIIa complex and/or through downstream genera-
tion of active coagulation factors (Booden et al, 2004; Palumbo et al,
2007). Furthermore, TF-FVIIa signalling via PAR-2 has been shown
to stimulate breast cancer cell migration (Jiang et al, 2004; Morris
et al, 2006), and a humanised anti-TF monoclonal antibody (CNTO
859) inhibited experimental in vivo lung metastasis from invasive
breast cancer cells by more than 99%, indicating a role for TF in
breast cancer cell metastasis (Ngo et al, 2007).
The cytoplasmic domain of TF seems to be essential for the
production of VEGF in human gastric cancer (Zhang et al, 2005)
and melanoma (Abe et al, 1999) cells. A positive feedback
mechanism induces upregulation of VEGF on tumour cells, further
increasing TF expression (Zhang et al, 1994). In addition, VEGF
has also been reported to induce TF expression in ECs, possibly
through early growth response gene-1 and sp1 transcription
factors (Armesilla et al, 1999; Mechtcheriakova et al, 1999). In
agreement with these studies, both TF and VEGF were expressed
by vessels at the earliest stages of dysplasia and by ECs associated
with in situ cancers in this study. However, interestingly, both
VEGF and TF were rarely expressed by vessels within invasive
carcinomas. This may be because of the fact that the plethora of
angiogenic molecules increases with malignant progression
(reviewed by Folkman, 2007), rendering the tumour less dependent
on EC-derived VEGF or TF. Our data suggest that, although VEGF
and TF are significant factors in promoting angiogenesis, other
molecules, for example, fibroblast growth factor-2 and platelet-
derived growth factor, may also have a significant role after
downregulation of VEGF and TF within intratumoural vessels
(upon tumour invasion).
This is the first report, to our knowledge, that significantly
correlates TF expression with MVD and proliferating ECs in the
hyperplasia, in situ and invasive breast carcinoma spectrum. The
association between VEGF and TF in ECs suggests a role for both
factors in tumour angiogenesis. Furthermore, the association
between VEGF and TF in invasive tumour cells, potentially
indicates an intimate relationship in breast cancer disease
progression, as has been previously shown (Ueno et al, 2000). In
addition, macrophages are a major population of infiltrating cells
in the tumour stroma; it is possible that VEGF and TF-expressing
macrophages, observed in this study, may have a role in regulating
the angiogenic switch and tumour progression in human breast
cancer, as previously described in an autochthonous mouse model
of breast cancer (Lin et al, 2006).
In conclusion, this is the first study to assess angiogenesis,
proliferating ECs, HIF-1a, VEGF and TF in each stage of the
hyperplasia, in situ and invasive breast carcinoma sequence in a
cohort of patients. These data suggest that the angiogenic switch
occurs at the onset of hyperplasia in the mammary milk duct
before any morphological evidence of atypia, although the greatest
increase in angiogenesis occurs between in situ and invasive
disease. Hypoxia-inducible factor-1a, VEGF and TF expression are
significantly associated with increased angiogenesis and prolifer-
ating ECs. Moreover, a significant association between VEGF and
TF in both ECs and invasive tumour cells suggests the importance
of both these factors in breast cancer angiogenesis, disease
progression and tumour biology. Further work is needed to
examine the precise relationship between VEGF and TF in breast
carcinogenesis, and to establish whether TF has a key independent
role in tumour angiogenesis and disease progression that is
functionally distinct from the role in VEGF production.
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